19eP Comparative efficacy and safety of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor-based adjuvant therapies in HR+/HER2- breast cancer: A network meta-analysis
作者
Y. Yin,C. Sun,X. Yan,T. Zeng
出处
期刊:ESMO open [Elsevier BV] 日期:2026-07-01卷期号:11: 107796-107796